After announcing a strategic expansion, Predictive Oncology Inc. (NASDAQ: POAI) has seen its shares gain significant momentum during the current market session. As of the latest check, POAI stock has surged by 109.35%, trading at $2.24 on the US stock charts.
Predictive Oncology Expanding Through AI/ML Driven Drug Discovery Platform
With the intention of finding novel biomarkers that can predict patient outcomes and treatment responses in cancer, Predictive Oncology has disclosed its ambitions to improve its AI/ML-driven drug development platform. In partnership with UPMC Magee-Womens Hospital, a retrospective investigation on ovarian cancer produced findings that served as inspiration for this biomarker identification project.
The results were showcased at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). Compared to clinical data alone, Predictive Oncology’s multi-omic machine learning models in the research were able to accurately identify critical traits and predict both short-term (two-year) and long-term (five-year) survival outcomes for patients with ovarian cancer.
Advancements and Broader Applicability
Predictive Oncology has conducted research and collected and evaluated data to facilitate the identification and creation of new biomarkers for ovarian cancer. We will investigate these indicators further, both on our own and in conjunction with biopharma businesses. The business has previously shown the effectiveness of its machine learning platform by using a variety of patient samples from biobanks to accurately predict medication reactions.
POAI is now advancing this process by applying state-of-the-art deep learning techniques for biomarker discovery related to patient overall survival (OS) and drug response. This platform enables the application of deep learning to appropriate patient cohorts, accelerating the initial stages of biomarker discovery.
The identification of novel cancer biomarkers presents a significant opportunity for Predictive Oncology’s platform, leveraging the extensive value of its diverse patient samples and data. This also opens potential new revenue streams for the company.
Market Potential
Predictive Oncology’s technology holds broad applicability, including the development of clinical decision support tools for clinical trial screening and informing drug discovery and development. These capabilities extend beyond ovarian cancer, potentially aiding in the discovery of biomarkers for other cancer types.
